From a673ba94fb3994c4daf68899d358d5e484afe567 Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Mon, 19 Feb 2024 16:11:13 +0100 Subject: [PATCH] [logseq-plugin-git:commit] 2024-02-19T15:11:12.320Z --- pages/STOP2030___Web.md | 5 ++--- 1 file changed, 2 insertions(+), 3 deletions(-) diff --git a/pages/STOP2030___Web.md b/pages/STOP2030___Web.md index 3cb24192..833b1550 100644 --- a/pages/STOP2030___Web.md +++ b/pages/STOP2030___Web.md @@ -45,11 +45,10 @@ - The fix-dose coformulation of Albendazole/Ivermectine is due to enter regulatory agencies - Acceptability and safety studies are underway - The access plan is being developed - - Investigadores principales de cada uno de los partners - - Ideas generales importantes - Integration across programs (these results have implications beyond STH) - Progress has been achieved through public-private partnerships but more partners are needed to reach the ultimate goal. - - El abstract del proyecto? + - ## Investigadores principales de cada uno de los partners + - ## Abstract del proyecto - [[Soil-Transmitted Helminths]] (STH) remain a significant public health problem with recognized obstacles for control and elimination with the current benzimidazole regimens in [[Mass Drug Administration]] (MDA) campaigns. Renewed targets from [[WHO]] for 2030 include elimination of [[STH]] morbidity in pre-school and school age children (PSAC & SAC), increased country governance and financial support and a strongyloidiasis control program; 2030 has also been targeted by [[WHO]] for controlling NTDs to attain the Sustainable Development Goals. The current proposal aims at accelerating the implementation of an innovative [[health]] technology, a [[Fixed-Dose Combination]] (FDC) tablet of co-formulated [[albendazole]] and ivermectin, with adequate safety and significantly superior efficacy against T. trichiura in a registrational randomized clinical trial. This trial is being conducted in Ethiopia, [[Kenya]] and Mozambique with the guidance of EMA and sponsored [[by]] [[EDCTP]] (STOP projects) with a Phase II trial completed and a Phase III currently recruiting.